News

The FDA approved Boruzu, a new presentation of bortezomib, for subcutaneous or intravenous administration in patients with multiple myeloma and mantle cell lymphoma.

This retrospective review demonstrates the increased use of active surveillance in patients with small nonfunctional pancreatic neuroendocrine tumors.

Pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia are receiving tisagenlecleucel in earlier lines of therapy.

Oral cannabis extract may be useful as an adjunct for chemotherapy-induced nausea and vomiting, although it may be associated with additional adverse events.

Enzalutamide produces strong indication of improvements in OS, PCS, TTS, and TTR compared with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC).

Michael Lai, ARNP, explained the mechanism of action of PARP inhibitors for the treatment of patients with prostate cancer.

Throughout August, the FDA approved drugs for the treatment of diseases including non-small cell lung cancer, cutaneous T-cell lymphoma, astrocytoma/oligodendroglioma, and endometrial cancer.

Minimal residual disease status was linked to progression-free survival in patients with chronic lymphocytic leukemia in the first-line treatment setting and with time-limited therapy.

Breakthrough therapy designation has been granted by the FDA to GSK5764227 for potential use in some patients with extensive-stage SCLC.

A gene assay was predictive of response to extended letrozole therapy, identifying a subset of patients with low-risk breast cancer with improved outcomes.

Compared to sunitinib, nivolumab plus ipilimumab showed increased overall survival and durable response benefits in patients with advanced renal cell carcinoma.

Oncology nurses are instrumental in assessing cancer-related fatigue and educating patients about potential interventions.

New guidelines for basal cell and squamous cell carcinoma provide detailed criteria for diagnosing, staging, IGRST, and follow-up, among others.

Compared with available literature, the rates of medication-related osteonecrosis of the jaw were higher in patients with breast cancer and bone metastases treated with antiresorptive therapy.

Higher corticosteroid peak dose may worse progression-free and overall survival in several tumor types including melanoma, non-small cell lung cancer, and others.

Increased use of consultations, breast MRIs, genetic counseling, and other testing in high-risk patients were a direct result from nurse-led high risk referral protocols.

Emotional intelligence becomes a critical tool for oncology nurses to sharpen when having difficult conversations with patients who received a terminal cancer diagnosis.

A phase 2 study reveals impactful objective response rates with manageable adverse events in patients with relapsed/refractory follicular lymphoma treated with odronextamab.

A learning approach integrating time series and static data may improve understanding of breast cancer outcomes.

A supplemental biologics license application has been accepted by the FDA for nivolumab plus ipilimumab as first-line treatment for unresectable hepatocellular carcinoma.

Fast track designation has been granted by the FDA to Deltacel with low-dose radiation for pretreated metastatic non–small cell lung cancer.

The Immune Effector Cell Encephalopathy score and keeping a close eye on patients’ symptoms are critical when monitoring for potential ICANS during lymphoma treatment.

Advanced practice providers with independent chemotherapy prescribing privileges reported positive responses related to readiness, confidence, and satisfaction.

A CRL has been issued by the FDA to the biologics license application seeking approval of linvoseltamab to treat some patients with multiple myeloma.

A behavioral intervention led by oncology nurses alleviated dyspnea in patients with advanced lung cancer, suggesting further research for long-term effects.

Early palliative care improved quality-of-life indicators including coping skills, self-management, and 2-year survival rate in adults with advanced cancer.

A multidisciplinary approach to adverse effect management addresses many needs patients with gynecologic cancers may have while undergoing treatment.

Although oncology nurses do not relay the initial information around impacted fertility with cancer treatment, they play an important role in guiding patients with any concerns around this topic.